Irodalom
Current advances in the diagnosis and treatment of pancreatic endocrine tumors.
VIOLA KV, SOSA JA. Curr Opin Oncol. 2005 Jan;17(1):24-7.
Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology.
TEMPERO MA, BEHRMAN S, BEN-JOSEF E, BENSON AB 3RD, CAMERON JL, CASPER ES, HOFFMAN JP, KARL
RC, KIM P, KOH WJ, KUVSHINOFF BW 2ND, MELVIN WS, MUSCARELLA P 2ND, SASSON AR, SHIBATA S, SHRIEVE
DC, TALAMONTI MS, TYLER DS, VICKERS SM, WARREN RS, WILLETT C, WOLFF RA; NATIONAL COMPREHENSIVE
CANCER NETWORK. J Natl Compr Canc Netw. 2005 Sep;3(5):598-626.
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of pancreatic
cancer.
HERRMANN R, JOST LM, PAVLIDIS N; ESMO GUIDELINES TASK FORCE. Ann Oncol. 2005;16 Suppl 1:i24-5.
Curative surgical treatment of inoperable pancreatic cancer after neoadjuvant therapy
ARKOSY P, SASI SL, ENYEDI A, SZANTO J, ANDRAS C, SAPY P. Magy Seb. 2005 Feb;58(1):29-33.
An outpatient with unresectable pancreatic cancer treated with gemcitabine
showing prolonged NC (22 months)
KOIZUMI M, SATA N, SHIMURA K, TSUKAHARA M, YOSHIZAWA K, KURIHARA K, HYODO M,YASUDA Y, NAGAI H. Gan
To Kagaku Ryoho. 2005 Dec;32(13):2133-6.
Investigating the potential of bevacizumab in other indications: metastatic
renal cell, non-small cell lung, pancreatic and breast cancer.
DE GRAMONT A, VAN CUTSEM E. Oncology. 2005;69 Suppl 3:46-56. Epub 2005 Nov 21.
Current management of locally advanced pancreatic cancer.
MAHESHWARI V, MOSER AJ. Nat Clin Pract Gastroenterol Hepatol. 2005 Aug;2(8):356-64.
A review of systemic therapy for advanced pancreatic cancer.
EL-RAYES BF, PHILIP PA. Clin Adv Hematol Oncol. 2003 Jul;1(7):430-4.
Recent updates on the role of chemotherapy in pancreatic cancer.
BURRIS HA 3RD. Semin Oncol. 2005 Aug;32(4 Suppl 6):S1-3.
Up-to-date diagnosis and treatment of advanced pancreatic cancer
STIELER JM, OETTLE H. Dtsch Med Wochenschr. 2005 Sep 23;130(38):2146-8.
Modern systemic therapy of advanced pancreatic cancer: impact on overall
survival and medico economical aspects
MAZZURI S, ROTH A. Rev Med Suisse. 2005 Jun 15;1(24):1616-20.
Anti-angiogenic therapy for gastrointestinal tumours
GRAEPLER F, GREGOR M, LAUER UM. Z Gastroenterol. 2005 Mar;43(3):317-29.
Photodynamic therapy for pancreatic and biliary tract carcinoma.
AYARU L, BOWN SG, PEREIRA SP. Int J Gastrointest Cancer. 2005;35(1):1-13.
Combined-modality treatment for operable pancreatic adenocarcinoma.
PISTERS PW, WOLFF RA, CRANE CH, EVANS DB.
Oncology (Williston Park). 2005 Mar;19(3):393-404, 409; discussion 409-10, 412-6.
Chemotherapy of pancreatic carcinoma
LUTZ MP. Schweiz Rundsch Med Prax. 2005 Jun 1;94(22):933-5.
Treatment for pancreatic cancer: current therapy and continued progress.
LOCKHART AC, ROTHENBERG ML, BERLIN JD. Gastroenterology. 2005 May;128(6):1642-54.
Chemotherapy for advanced pancreatic cancer: past, present, and future.
FRIBERG G, KINDLER HL. Curr Oncol Rep. 2005 May;7(3):186-95.
Molecular markers of early pancreatic cancer.
GOGGINS M. J Clin Oncol. 2005 Jul 10;23(20):4524-31.
Bevacizumab as treatment for chemotherapy-resistant pancreatic cancer.
BRUCKNER HW, HREHOROVICH VR, SAWHNEY HS. Anticancer Res. 2005 Sep-Oct;25(5):3637-9.
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central
Cancer Treatment Group (NCCTG) randomized phase II study.
ALBERTS SR, FOSTER NR, MORTON RF, KUGLER J, SCHAEFER P, WIESENFELD M, FITCH TR, STEEN P, KIM GP, GILL
S. Ann Oncol. 2005 Oct;16(10):1654-61. Epub 2005 Aug 5.
Locally advanced pancreatic cancer.
WILLETT CG, CZITO BG, BENDELL JC, RYAN DP. J Clin Oncol. 2005 Jul 10;23(20):4538-44.
A novel anti-pancreatic cancer agent, LY293111.
DING XZ, TALAMONTI MS, BELL RH JR, ADRIAN TE. Anticancer Drugs. 2005 Jun;16(5):467-73.
The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation.
ASANO T, YAO Y, ZHU J, LI D, ABBRUZZESE JL, REDDY SA. Biochem Biophys Res Commun. 2005 May
27;331(1):295-302.
An early phase II study of S-1 in patients with metastatic pancreatic cancer.
UENO H, OKUSAKA T, IKEDA M, TAKEZAKO Y, MORIZANE C. Oncology. 2005;68(2-3):171-8. Epub 2005 Jul 4.
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic
cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).
DI COSTANZO F, CARLINI P, DONI L, MASSIDDA B, MATTIOLI R, IOP A, BARLETTA E, MOSCETTI L, RECCHIA F,
TRALONGO P, GASPERONI S. Br J Cancer. 2005 Jul 25;93(2):185-9.
Prolonged fi xed dose rate infusion of gemcitabine with autologous haemopoietic support in
advanced pancreatic adenocarcinoma.
BENGALA C, GUARNERI V, GIOVANNETTI E, LENCIONI M, FONTANA E, MEY V, FONTANA A, BOGGI U, DEL CHIARO M,
DANESI R, RICCI S, MOSCA F, DEL TACCA M, CONTE PF. Br J Cancer. 2005 Jul 11;93(1):35-40.
Erlotinib and chemoradiation followed by maintenance erlotinib for locally
advanced pancreatic cancer: a phase I study.
IANNITTI D, DIPETRILLO T, AKERMAN P, BARNETT JM, MAIA-ACUNA C, CRUFF D, MINER T,MARTEL D, CIOFFI W,
REMIS M, KENNEDY T, SAFRAN H. Am J Clin Oncol. 2005 Dec;28(6):570-5.
Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer
and prognostic factors.
SEZGIN C, KARABULUT B, USLU R, SANLI UA, GOKSEL G, YUZER Y, GOKER E. Scand J Gastroenterol. 2005
Dec;40(12):1486-92.
Combination therapy for advanced pancreatic cancer using Herceptin plus
chemotherapy.
BUCHLER P, REBER HA, EIBL G, ROTH MA, BUCHLER MW, FRIESS H, ISACOFF WH, HINES OJ. Int J Oncol. 2005
Oct;27(4):1125-30.
Current diagnosis and treatment of pancreatic cancer
HEINRICH S, SCHAFER M, BAUERFEIND P, PESTALOZZI BC, CLAVIEN PA. Schweiz Rundsch Med Prax. 2005
Aug 17;94(33):1243-54.
Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected
pancreatic cancer.
A hasnyálmirigy | 353
354 | Gastro Update 2006
KHORANA AA, HU YC, RYAN CK, KOMOROWSKI RA, HOSTETTER G, AHRENDT SA. J Gastrointest Surg. 2005
Sep-Oct;9(7):903-11.
Celiac axis infusion and microembolization for advanced stage III/IV pancreatic cancer–a phase II
study on 265 cases.
AIGNER KR, GAILHOFER S. Anticancer Res. 2005 Nov-Dec;25(6C):4407-12.
Adjuvant treatment for resectable pancreatic cancer.
CHUA YJ, CUNNINGHAM D. J Clin Oncol. 2005 Jul 10;23(20):4532-7.
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable
or metastatic pancreatic cancer.
OETTLE H, RICHARDS D, RAMANATHAN RK, VAN LAETHEM JL, PEETERS M, FUCHS M, ZIMMERMANN A, JOHN W, VON
HOFF D, ARNING M, KINDLER HL. Ann Oncol. 2005 Oct;16(10):1639-45. Epub 2005 Aug 8.
Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice.
JIA L, ZHANG MH, YUAN SZ, HUANG WG. World J Gastroenterol. 2005 Jan 21;11(3):447-50.
Survey of gemcitabine treatment for advanced pancreatic cancer in 20 hospitals of Nagano
Prefecture
MAEJIMA S, TAKEUCHI N, HASEBE O, MATSUDA Y, HANAZAKI K, KAJIKAWA S, MUKAWA K,HOSOKAWA K, HAYASHI K,
HISA T, FURUTA K, TAJIRI K, FUJIMORI Y, KANEKO G, OCHI Y,SHIKAMA N, KAWA S, MIYAGAWA S, MIWA S, KIYOSAWA
K; NAGANO PANCREATIC CANCERSTUDY GROUP. Gan To Kagaku Ryoho. 2005 Aug;32(8):1129-33.
Carboplatin plus gemcitabine in patients with inoperable or metastatic
pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group.
XIROS N, PAPACOSTAS P, ECONOMOPOULOS T, SAMELIS G, EFSTATHIOU E, KASTRITIS E, KALOFONOS H, ONYENADUM A,
SKARLOS D, BAMIAS A, GOGAS H, BAFALOUKOS D, SAMANTAS E, KOSMIDIS P. Ann Oncol. 2005 May;16(5):773-
9. Epub 2005 Mar 31.
Intraperitoneal and intrapleural gemcitabine in patients with advanced
pancreatic cancer
AKIYAMA T, HOMMA H, MEZAWA S, TAKAHASHI S, KOIKE K, KOGAWA K, HIRATA K. Gan To Kagaku Ryoho. 2005
Oct;32(11):1712-4.
Changes in tumor marker levels as a predictor of gemcitabine effect on patients with unresectable
or recurrent pancreatic cancer
TENDO M, NAKATA B, NISHINO H, INOUE M, KOSAKA K, AMANO R, YAMADA N, HIRAKAWA K. Gan To Kagaku
Ryoho. 2005 Jun;32(6):795-8.
Oxaliplatin for pretreated patients with advanced or metastatic pancreatic
cancer: a multicenter phase II study.
ANDROULAKIS N, SYRIGOS K, POLYZOS A, ARAVANTINOS G, STATHOPOULOS GP, ZIRAS N,MALLAS K, VAMVAKAS L,
GEORGOULIS V; HELLENIC ONCOLOGY RESEARCH GROUP. Cancer Invest. 2005;23(1):9-12.
A phase II trial of raltitrexed (Tomudex) in advanced pancreatic and biliary carcinoma.
FRANCOIS E, HEBBAR M, BENNOUNA J, MAYEUR D, PERRIER H, DORVAL E, MARTIN C, BOURGEOIS H, BARTHELEMY
P, DOUILLARD JY. Oncology. 2005;68(4-6):299-305. Epub 2005 Jul 12.
